Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ODU
|
|||
| Former ID |
DIB010524
|
|||
| Drug Name |
Belerofon
|
|||
| Synonyms |
IFNa
Click to Show/Hide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Nautilus Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interferon alpha/beta receptor 1 (IFNAR1) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Natural killer cell mediated cytotoxicity | ||||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | Interferon alpha/beta signaling | |||
| Regulation of IFNA signaling | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Interferon type I signaling pathways | ||||
| Interferon alpha/beta signaling | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug. Nautilus Biotech. MAY 14, 2007. | |||
| REF 2 | WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.